Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ARS Pharmaceuticals, Inc(SPRY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SPRY
09/25/2026: SPRY (1-star) is currently NOT-A-BUY. Pass it for now.
ARS Pharmaceuticals, Inc is a biotechnology company focused on the commercialization of neffy, a needle-free nasal epinephrine spray designed for severe allergic reactions. Its primary strength lies in its innovative delivery technology, which aims to improve patient compliance by offering a non-invasive alternative to traditional auto-injectors. The company's main investment story is the potential for neffy to capture significant market share from established auto-injector incumbents. Key risks include the difficulty of shifting entrenched clinical practices, reliance on a single core product, and the impact of insurance reimbursement policies. The stock may best suit growth-oriented investors who should monitor adoption trends and market penetration rates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Investors seeking exposure to a disruptive biotechnology platform in the allergy space may find the company's growth profile appealing. |
| Momentum investor | Strong fit while signal remains positive | The stock can be volatile, potentially offering opportunities for momentum-based strategies during periods of positive news or adoption trends. |
| Value investor | Weak fit | The company lacks the established earnings and cash flows necessary to support a traditional value-based investment thesis. |
| Dividend investor | Weak fit | The company does not pay a dividend and prioritizes capital allocation toward growth and commercialization. |
| Low-risk investor | Weak fit | The inherent risks of biotechnology commercialization and clinical reliance make this a high-volatility, higher-risk investment. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a growth-stage biotech, news events can trigger sharp price movements. |
| Valuation risk | Medium / high | The stock valuation depends heavily on future adoption curves rather than current fundamental earnings. |
| Competition risk (Auto-injector incumbents) | High | Incumbent products have strong brand recognition and low costs that create significant market friction. |
| Business quality | Medium | The company is at a pivotal early stage with a single core product platform. |
| Dividend income | Low / none | The company does not generate the cash flow required for dividend payments. |
| Execution risk | High | Successful commercialization of a new device requires significant adoption by patients and physicians. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -19.2% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 405.75M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 1.6M shares | Beta 1 | 52 Weeks Range 4.02 - 13.15 | Updated Date 09/25/2026 |
52 Weeks Range 4.02 - 13.15 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.18 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Pharmaceutical Sales | Revenue generated from the commercial sale of its lead product, neffy. | The company earns money by selling a specialized medical product to patients with severe allergies. |
| Geography | Primary operations focused on the US market, with potential for international expansion. | Most revenue is generated in the US, making US healthcare policy and insurance reimbursement critical factors. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 369.02M | Price to Sales(TTM) 3.47 |
Enterprise Value 369.02M | Price to Sales(TTM) 3.47 | ||
Enterprise Value to Revenue 3.16 | Enterprise Value to EBITDA -9.88 | Shares Outstanding 99.45M | Shares Floating 48.03M |
Shares Outstanding 99.45M | Shares Floating 48.03M | ||
Percent Insiders 16.18 | Percent Institutions 92.08 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About ARS Pharmaceuticals, Inc
Exchange NASDAQ | Headquarters San Diego, CA, United States | ||
IPO Launch date 2020-12-04 | CEO, President & Director Mr. Donn Casale | ||
Sector Healthcare | Industry Biotechnology | Full time employees 195 | Website https://ars-pharma.com |
Full time employees 195 | Website https://ars-pharma.com | ||
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.